Drug Trial Radar · NCT05903092
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Sep 26, 2023
Primary completion
Oct 31, 2029
Study completion Oct 31, 2030
Sponsor
- Lead sponsor
- Khalil ChoucairAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AstraZeneca; Barbara Ann Karmanos Cancer Institute
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks for 4 cycles. After 4 cycles, subjects will continue maintenance treatment with durvalumab plus monalizumab every 4 weeks until disease progression, unacceptable toxicity, decision to stop study treatment, or withdrawal of consent. Patients who have received one prior cycle of treatment before enrolling on the study will receive a total of 4 cycles with monalizumab, durvalumab, and chemotherapy. There will be a safety lead-in phase, including 6 to 12 patients, to confirm the safety of the proposed dose of monalizumab to use in combination with chemotherapy and durvalumab. MOZART-LS cohort: Study treatment will consist of durvalumab and monalizumab following standard of care chemo-radiation consisting of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide for 3-4 cycles and standard dose radiation. Radiation therapy should have started before completion of cycle 2 of chemotherapy. NOTE: Subjects who have non-progressive disease and meet the eligibility criteria can start study treatment up to 56 days from completion of chemo-radiation. Durvalumab and monalizumab will be administered every 4 weeks for up to 2 years (26 cycles), disease progression, unacceptable toxicity, decision to stop study treatment, or withdrawal consent, whichever occurs first.
Conditions
- Small Cell Lung Cancer
- SCLC
- Extensive Stage Small Cell Lung Cancer
- Limited Stage Small-Cell Lung Cancer
Interventions
DurvalumabDrug
1500mg IV on Day 1 of every Cycle
MonalizumabDrug
1500mg IV on Day 1 of every Cycle
Carboplatin or CisplatinDrug
On Day 1 of Cycles 1-4 by IV: Carboplatin: AUC 5-6 OR Cisplatin: 75-80mg/m\^2
EtoposideDrug
80-100mg/m\^2 IV on Days 1-3 of Cycles 1-4
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1 year Progression Free Survival (PFS)Time frame: 1 year
- Safety and TolerabilityTime frame: 24 Months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana · Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
Karmanos Cancer Center (Wayne State University)
Detroit, Michigan · Recruiting
University of Virginia Health System
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.